dc.contributor.advisor | Rahman, Kazi Fatema | |
dc.contributor.author | Eva, Israt Ara Jannat | |
dc.date.accessioned | 2023-01-18T09:50:46Z | |
dc.date.available | 2023-01-18T09:50:46Z | |
dc.date.copyright | 2022 | |
dc.date.issued | 2022-04 | |
dc.identifier.other | ID 18146047 | |
dc.identifier.uri | http://hdl.handle.net/10361/17764 | |
dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. | en_US |
dc.description | Cataloged from PDF version of thesis. | |
dc.description | Includes bibliographical references (pages 36-49). | |
dc.description.abstract | The novel CRISPR/Cas system is an effective and widely used gene-editing tool that has created the opportunity to study gene function and understand the pathogenic mechanisms underlying various genetic disorders. It has uncovered the pathophysiology of several previously unsolved medical conditions and is currently an essential genome-editing tool being employed to develop new drugs and innovative gene therapies for potentially life-threatening diseases such as, cancer and Duchenne muscular dystrophy (DMD). The specificity, accuracy, high probability of successful outcomes, cost and time effectiveness of CRISPR/Cas systems have made it a reliable means to treat cancer and DMD over other previously used genetic modification tools. This review will discuss how CRISPR/Cas can be utilized to design in vivo and in vitro disease models, target cancer cells, and aid in the identification of novel drug targets to treat cancer and DMD patients. | en_US |
dc.description.statementofresponsibility | Israt Ara Jannat Eva | |
dc.format.extent | 49 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | CRISPR/Cas9 mechanism | en_US |
dc.subject | In vivo and in vitro modeling | en_US |
dc.subject | CRISPR/Cas9 delivery | en_US |
dc.subject | Mutation targeting in cancer and DMD | en_US |
dc.subject | Chromosomal rearrangement | en_US |
dc.subject | Mouse modeling | en_US |
dc.subject | Off-target limitation | en_US |
dc.subject | DMD mutation in human iPSCs | en_US |
dc.subject | Myoediting of DMD | en_US |
dc.subject | Therapeutic application of CRISPR | en_US |
dc.subject.lcsh | Molecular genetics | |
dc.subject.lcsh | Molecular genetics | |
dc.subject.lcsh | Cancer--Treatment | |
dc.title | CRISPR: a revolutionary tool for modeling and treating cancer and Duchenne muscular dystrophy | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | Department of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |